← Leaderboards
Dan Thomas Stinchcomb
Inviragen, Inc.
$8,342,763
Attributed
$8,611,537
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2006–17$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,611,537 · 8
By mechanism
N01$3,191,811 · 1
U01$2,873,420 · 1
R43$1,492,047 · 3
R41$588,355 · 1
R21$312,550 · 1
U54$153,354 · 1
Top collaborators
- Neal Scott Van Hoeven2 shared
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesSafetyAttenuatedBaseVirusImmune ResponseViralVaccine DevelopmentDoseInfectionNonhuman PrimateImmunogenicityVectorCulicidaeDengueAfricaImmunogenicCountryResponseUniversitiesLeadNeutralizing AntibodyAnimalsGenetic
Grant awards (15)
Development of an Innovative, Effective RNA-based Vaccine for Chikungunya Virus$224,998
R43 · FY2017 · AI
Development of an Innovative, Effective, RNA-based Vaccine for Zika Virus$312,550
R21 · FY2016 · AI
Development of Technologies to Facilitate the Use of and Response to Vaccines$1,358,731
N01 · FY2011 · AI · contact PI
Development of Technologies to Facilitate the Use of and Response to Vaccines$1,833,080
N01 · FY2010 · AI · contact PI
Second Generation Dengue Vaccine$299,993
R43 · FY2010 · AI · contact PI
Preclinical development of a chimeric tetravalent dengue vaccine$487,622
U01 · FY2009 · AI · contact PI
Second Generation Dengue Vaccine$299,977
R43 · FY2009 · AI · contact PI
Preclinical development of a chimeric tetravalent dengue vaccine$771,968
U01 · FY2008 · AI · contact PI
MVA-based vaccines against highly pathogenic avian influenza$288,653
R41 · FY2008 · AI · contact PI
Animal Models and Preclinical Development of a Chimeric Chikungunya Vaccine$153,354
U54 · FY2008 · AI · contact PI
Preclinical development of a chimeric tetravalent dengue vaccine$1,195,165
U01 · FY2007 · AI · contact PI
Mucosal modified vaccinina Ankara-based plaque vaccines$309,521
R43 · FY2007 · AI · contact PI
MVA-based vaccines against highly pathogenic avian influenza$299,702
R41 · FY2007 · AI · contact PI
Preclinical development of a chimeric tetravalent dengue vaccine$418,665
U01 · FY2006 · AI · contact PI
Mucosal modified vaccinina Ankara-based plaque vaccines$357,558
R43 · FY2006 · AI · contact PI